Adams L. Sibley , Kathryn E. Muessig , Seth M. Noar , Nisha Gottfredson O'Shea , William C. Miller , Vivian F. Go
{"title":"Promoting substance use stigma resistance through an automated text message intervention (project RESTART): Outcomes of a pilot feasibility trial","authors":"Adams L. Sibley , Kathryn E. Muessig , Seth M. Noar , Nisha Gottfredson O'Shea , William C. Miller , Vivian F. Go","doi":"10.1016/j.josat.2025.209671","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Stigma in people who use drugs predicts treatment engagement, psychosocial health, and overdose, yet there are few evidence-based interventions to support people who use drugs in managing and coping with substance-related stigma and even fewer for people in active use. mHealth is one option to engage this hard-to-reach population.</div></div><div><h3>Methods</h3><div>Premised on the theory of stigma resistance, this mixed-methods study explored the feasibility, acceptability, and preliminary effectiveness of Project RESTART, a four-week, automated text message intervention for rural-dwelling people who use drugs (<em>n</em> = 30) using a one-group pre-post design. The study recruited participants from syringe service programs and by word-of-mouth.</div></div><div><h3>Results</h3><div>Key outcomes included high retention (90 %), message engagement (median responses: 4, interquartile range: 1–17), acceptability (mean item score: 3.55, standard deviation: 0.34, range: 1–4), and preliminary effectiveness in the main outcomes (Cohen's d: stigma resistance (0.56), self-stigma (0.50)). Results were corroborated in sub-sample follow-up interviews (<em>n</em> = 13).</div></div><div><h3>Conclusion</h3><div>These promising findings suggest text messaging is a feasible and acceptable modality for delivering stigma education and coping resources. Effectiveness should be established in a full-scale randomized controlled trial. This trial was registered at <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> on February 20, 2024 (<span><span>NCT06281548</span><svg><path></path></svg></span>).</div></div>","PeriodicalId":73960,"journal":{"name":"Journal of substance use and addiction treatment","volume":"172 ","pages":"Article 209671"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of substance use and addiction treatment","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949875925000505","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Stigma in people who use drugs predicts treatment engagement, psychosocial health, and overdose, yet there are few evidence-based interventions to support people who use drugs in managing and coping with substance-related stigma and even fewer for people in active use. mHealth is one option to engage this hard-to-reach population.
Methods
Premised on the theory of stigma resistance, this mixed-methods study explored the feasibility, acceptability, and preliminary effectiveness of Project RESTART, a four-week, automated text message intervention for rural-dwelling people who use drugs (n = 30) using a one-group pre-post design. The study recruited participants from syringe service programs and by word-of-mouth.
Results
Key outcomes included high retention (90 %), message engagement (median responses: 4, interquartile range: 1–17), acceptability (mean item score: 3.55, standard deviation: 0.34, range: 1–4), and preliminary effectiveness in the main outcomes (Cohen's d: stigma resistance (0.56), self-stigma (0.50)). Results were corroborated in sub-sample follow-up interviews (n = 13).
Conclusion
These promising findings suggest text messaging is a feasible and acceptable modality for delivering stigma education and coping resources. Effectiveness should be established in a full-scale randomized controlled trial. This trial was registered at ClinicalTrials.gov on February 20, 2024 (NCT06281548).